Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1375 of 1475 entries
View as:

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Phase: N/A Priority: Normal
NCT ID: NCT02181738 Org: User:
Start: 08/12/14 End: 12/27/22 Due: 12/27/23

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Phase: N/A Priority: Normal
NCT ID: NCT00114777 Org: User:
Start: 02/28/05 End: 09/30/14 Due: 09/30/15

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02110082 Org: User:
Start: 04/30/14 End: 12/31/16 Due: 12/31/17

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01511913 Org: User:
Start: 06/03/12 End: 12/12/19 Due: 12/12/20

Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe

Phase: N/A Priority: Normal
NCT ID: NCT01890473 Org: User:
Start: 07/31/13 End: 11/30/14 Due: 11/30/15

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

Phase: N/A Priority: Normal
NCT ID: NCT01340586 Org: User:
Start: 06/30/11 End: 09/30/11 Due: 09/30/12

Single Dose Study of BMS-820836

Phase: N/A Priority: Normal
NCT ID: NCT00964912 Org: User:
Start: 07/31/08 End: 04/30/09 Due: 04/30/10

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02472977 Org: User:
Start: 07/13/15 End: 01/27/17 Due: 01/27/18

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01585987 Org: User:
Start: 07/31/12 End: 04/30/15 Due: 04/30/16

A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05014438 Org: User:
Start: 08/17/21 End: 08/22/22 Due: 08/22/23

BMS-599626 in Patients With Advanced Solid Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00095537 Org: User:
Start: 03/31/04 End: - Due: -

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04301310 Org: User:
Start: 03/09/20 End: 03/16/20 Due: 03/16/21

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Phase: N/A Priority: Normal
NCT ID: NCT02279862 Org: User:
Start: 12/02/14 End: 12/15/16 Due: 12/15/17

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Phase: N/A Priority: Normal
NCT ID: NCT01492504 Org: User:
Start: 02/07/12 End: 03/19/18 Due: 03/19/19

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

Phase: N/A Priority: Normal
NCT ID: NCT00796991 Org: User:
Start: 02/28/09 End: 10/31/12 Due: 10/31/13

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT04567667 Org: User:
Start: 10/15/20 End: 04/11/21 Due: 04/11/22

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Phase: N/A Priority: Normal
NCT ID: NCT04766476 Org: User:
Start: 02/24/21 End: 08/12/21 Due: 08/12/22

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01830205 Org: User:
Start: 09/30/12 End: 06/30/13 Due: 06/30/14

A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT06476834 Org: User:
Start: 06/24/24 End: 11/02/24 Due: 11/02/25

A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02593786 Org: User:
Start: 01/07/16 End: 09/27/21 Due: 09/27/22

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05328908 Org: User:
Start: 04/28/22 End: 09/30/25 Due: 09/30/26

A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Phase: N/A Priority: Normal
NCT ID: NCT06549608 Org: User:
Start: 04/20/24 End: 04/18/25 Due: 04/18/26

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Phase: N/A Priority: Normal
NCT ID: NCT01692366 Org: User:
Start: 11/30/12 End: 03/31/14 Due: 03/31/15

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02017717 Org: User:
Start: 02/07/14 End: 06/21/24 Due: 06/21/25

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

Phase: N/A Priority: Normal
NCT ID: NCT01425970 Org: User:
Start: 05/31/12 End: 08/31/13 Due: 08/31/14